AiRuiKa (camrelizumab) / CG Invites, Jiangsu Hengrui Pharma, HLB Bio Group, NPO Petrovax - LARVOL DELTA

Rechallenge of anti-PD-1 antibody combined with chemotherapy shows promising efficacy in the treatment of advanced metastatic hepatocellular carcinoma: A case report. (PubMed, Oncol Lett) - "The lung metastasis progressed multiple times while the patient was undergoing successive treatments with Lenvatinib, Apatinib combined with Camrelizumab and Regorafenib. The patient has been receiving Tislelizumab combined with Xelox for 23 months and has maintained a complete response to treatment. This case indicates that combining immune rechallenge with chemotherapy is beneficial for metastatic hepatocellular carcinoma."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor

PD-1 Inhibitor Combined With 125I Seed Implantation for Hepatocellular Carcinoma's Extrahepatic Metastasis: Efficacy and Safety (clinicaltrials.gov) - P=N/A | N=80 | Completed | Sponsor: Jiangxi Provincial Cancer Hospital

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: A network meta-analysis. (ASCO 2025) - "For overall survival, the NMA indicated that Cetuximab plus chemotherapy significantly reduced the risk of death at 6 months (HR = 0.3750, 95%CI [0.1676; 0.8389]; p-value = 0.0170), while Tislelizumab plus chemotherapy was most effective at 12 and 18 months in comparison to chemotherapy alone (HR = 0.6588, 95%CI [0.5581; 0.7776]; p-value < 0.0001) and (HR = 0.8114, 95%CI [0.7237; 0.9098]; p-value = 0.0003), respectively. At 24 months, Nivolumab plus Ipilimumab was most effective (HR = 0.8942, 95%CI [0.8442; 0.9472]; p-value = 0.0001). For PFS, Camrelizumab plus chemotherapy was most effective at 6 months (HR = 0.7610, 95%CI [0.6665; 0.8689] p-value < 0.0001), and Sintilimab plus chemotherapy at 12 months (HR = 0.8472, 95%CI [0.7946; 0.9032]; p-value < 0.0001). Pembrolizumab plus chemotherapy was most effective at 18 and 24 months (HR = 0.9087, 95%CI [0.8632; 0.9567]; p-value = 0.0003) and (HR = 0.9596, 95%CI [0.9328; 0.9871]; p-value = 0.0043), respectively......"

Metastases • Retrospective data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

The Effect of Serum Ferritin in irAE (clinicaltrials.gov) - P=N/A | N=1500 | Recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

Adverse events • IO biomarker • New trial • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

Efficacy and safety of different PD-1 inhibitors combined with chemotherapy in locally advanced head and neck squamous cell carcinoma. (ASCO 2025) - "All patients received neoadjuvant chemotherapy combined with one kind of PD-1 inhibitors (pembrolizumab, camrelizumab, tislelizumab, toripalimab, sintilimab), followed by surgery and adjuvant radiotherapy or definitive chemoradiotherapy. Neoadjuvant chemoimmunotherapy have demonstrated promising efficacy and safety in HNSCC. Pembrolizumab or toripalimab with chemotherapy showed improved PFS compared with tislelizumab. Further studies are required to evaluate the survival benefits of the treatment."

Clinical • Metastases • Alopecia • Fatigue • Head and Neck Cancer • Immunology • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A retrospective pilot study of neoadjuvant chemotherapy combined with immunotherapy in the treatment of thoracic esophageal squamous cell carcinoma with cervical lymph node metastasis. (ASCO 2025) - "19 patients received camrelizumab, nab-paclitaxel, and S-1 regimen and 1 received tislelizumab, nab-paclitaxel and nedaplatin regimen. With manageable safety profiles, high pathological response rates and enhanced survival rates, neoadjuvant CIT shows significant potential for improving clinical outcomes in ESCC and CLNM. Further prospective trials are needed to fully evaluate the effectiveness and safety of this treatment strategy for these patients. Baseline Characteristics of the Patients"

Retrospective data • Anemia • Cervical Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Infectious Disease • Oncology • Pneumonia • Respiratory Diseases • Squamous Cell Carcinoma

EFFICACY AND SAFETY OF ANTI-PD-1/PD-L1 ANTIBODIES IN PATIENTS WITH RELAPSED REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A META-ANALYSIS (EHA 2025) - "Given the availability of several proprietary PD-1 antibodies in China, our search strategy included not only the keywords "PD-1 blockade" or "Programmed Death-1 Blockade," but also specific brand names such as Pembrolizumab, Nivolumab, Sintilimab, Camrelizumab, Tislelizumab, and Toripalimab. Overall, PD-1/PD-L1 inhibitors demonstrated suboptimal therapeutic efficacy in the selected trials for R/R DLBCL. However, combining PD-1/PD-L1 inhibitors with Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) showed potential for improved treatment outcomes. Additionally, PD-1/PD-L1 inhibitors were found to be safe and well-tolerated in patients with R/R DLBCL."

Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lung Cancer • Lymphoma • Melanoma • Multiple Myeloma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

CCGLC-001: Combined HAIC, TKI/anti-VEGF and ICIs As Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Ze-yang Ding, MD | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Apr 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

T+I+XELOX: Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC (clinicaltrials.gov) - P=N/A | N=68 | Completed | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active, not recruiting ➔ Completed

Trial completion • Hepatocellular Cancer • Oncology • Solid Tumor

SPRING: Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS (clinicaltrials.gov) - P2 | N=200 | Not yet recruiting | Sponsor: Peking University Shenzhen Hospital

Biomarker • New P2 trial • Oncology

The Importance of Timing in Immunotherapy: A Systematic Review. (PubMed, Cureus) - "Only ICIs were considered, including monotherapies of nivolumab, pembrolizumab, atezolizumab, durvalumab, ipilimumab, camrelizumab, tislelizumab, sintilimab, and combination therapies of nivolumab plus ipilimumab or ICIs with additional agents such as atezolizumab with bevacizumab or pembrolizumab with axitinib. These results suggest that the timing of immunotherapy administration may significantly impact treatment efficacy, potentially due to interactions with circadian rhythms. Further research is needed to establish standardized guidelines for optimizing infusion timing to enhance patient outcomes."

Journal • Review • Genito-urinary Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Integrating quality of life and overall survival to quantify benefit from frontline systemic therapy options in unresectable/advanced hepatocellular carcinoma: a network meta-analysis (EASL 2025) - " Ten studies, enrolling 7,268 patients treated with Sorafenib, Lenvatinib, Nivolumab, Tislelizumab, Durvalumab, Atezolizumab+Bevacizumab, Sintilimab+IBI305, Durvalumab+Tremelimumab, Nivolumab+Ipilimumab, Atezolizumab+Cabozantinib, Lenvatinib+Pembrolizumab, Camrelizumab+Apatinib were included... Atezolizumab plus Bevacizumab was associated with the highest magnitude in reducing the risk of deterioration of most HR-QoL domains compared to other systemic therapies. Integrated assessment of OS with HR-QoL assessed by MDC suggests atezolizumab plus bevacizumab to provide the best balance between QoL preservation and OS benefit compared to other systemic therapy options in unresectable/advanced HCC."

HEOR • Metastases • Retrospective data • Fatigue • Hepatocellular Cancer • Hepatology • Oncology • Pain • Solid Tumor

Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Fudan University | Trial completion date: Mar 2025 ➔ Aug 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Immunotherapy combined with chemotherapy: a promising therapeutic approach in the management of colonic squamous cell carcinoma-a case report. (PubMed, Front Oncol) - "Therefore, the treatment plan has been adjusted to include nab-paclitaxel and carboplatin, in combination with camrelizumab, an Anti-PD-1 therapy, for antitumor therapy. The combination therapy resulted in a partial response. This case highlights the potential efficacy of Anti-PD-1 therapy combined with chemotherapy in CSCC, suggesting a possible treatment approach for this rare cancer subtype."

Journal • Chronic Obstructive Pulmonary Disease • Colorectal Cancer • Diabetes • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Metabolic Disorders • Microsatellite Instability • Oncology • Pain • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma • Varicose Veins

Do Utility Scores Derived From Different Preference-Based Measurements Influence the Results of Cost-Effectiveness Analysis? (ISPOR 2025) - "The model B was built to compare sintilimab with camrelizumab as 1 st -line therapy. The model C was built to compare anlotinib with support care as 3 rd -line therapy... In model A, when utilities were measured by Q-5D-5L, compared with chemotherapy, alectinib provided 1.91 additional QALYs (10.08 QALYs vs. 8.18 QALYs)... The utilities measured by EQ-5D-5L were higher than those measured by SF-6Dv2, and the utilities measured by SF-6Dv2 were more clustered across different health states. Compared to using the utilities measured by SF-6Dv2, using EQ-5D-5L results in a higher QALY and larger incremental QALY. This difference would further expand as the patient’s survival time increases."

Cost effectiveness • HEOR • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Efficacy of immune checkpoint inhibitors (ICIs) in advanced large cell neuroendocrine carcinoma (LCNEC) of the lung: A systematic review and meta-analysis. (ASCO 2025) - "The most common ICIs across the cohort were atezolizumab, camrelizumab, nivolumab, and pembrolizumab. ICIs have become the standard of care for treating SCLC and NSCLC in various combinations. ICIs, based on our meta-analysis, have also demonstrated encouraging results in advanced LCNEC. However, tumor factors such as molecular subtypes, genomic profiles, and other predictors influencing the response to ICIs need to be elucidated."

Checkpoint inhibition • Metastases • Retrospective data • Review • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Outcomes of immunotherapy in advanced osteosarcoma patients: A systematic review and meta-analysis. (ASCO 2025) - "The most commonly used immunotherapies included tumor-infiltrating lymphocytes (TIL) monotherapy or in combination with nivolumab (46%, n = 160) and Camrelizumab (32%, n = 111). This meta-analysis shows promising results for immunotherapy in osteosarcoma treatment and highlights the need for prospective trials with larger patient populations to understand immunotherapy outcomes in osteosarcoma better."

Metastases • Retrospective data • Review • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

First-line treatment with surufatinib, camrelizumab, nab-paclitaxel, and S-1 in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): A phase Ib/II randomized study. (ASCO 2025) - P1/2 | "In phase II, patients were randomized 1:1 to receive the NASCA regimen or nab-paclitaxel plus gemcitabine (AG). The NASCA regimen demonstrated promising efficacy with a manageable safety profile, showing a significantly higher ORR and longer PFS compared to AG group in patients with locally advanced or metastatic PDAC. Further studies are warranted to confirm these findings."

Clinical • Metastases • P1/2 data • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CD8

Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study. (ASCO 2025) - P1/2 | "The combination of fruquintinib, camrelizumab, paclitaxel liposome, and nedaplatin demonstrated significant efficacy and manageable toxicity profile as a first-line treatment for advanced ESCC, suggesting a potential new treatment strategy."

Clinical • Combination therapy • Metastases • P2 data • Anemia • Cardiovascular • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Hematological Disorders • Hypertension • Leukopenia • Mucositis • Neutropenia • Oncology • Pain • Squamous Cell Carcinoma • Stomatitis

Consolidative camrelizumab following definitive concurrent chemoradiotherapy with involved-field irradiation in locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 trial. (ASCO 2025) - P2 | "The PACIFIC study demonstrated that consolidation durvalumab significantly improves overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) after dCCRT. Consolidative camrelizumab following definitive concurrent chemoradiotherapy with IFI shows promising efficacy and manageable toxicity in patients with unresectable locally advanced ESCC."

Metastases • P2 data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Infectious Disease • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Respiratory Diseases • Squamous Cell Carcinoma

Comprehensive analysis on reactive cutaneous capillary endothelial proliferation following camrelizumab-based therapy in patients with solid tumors: A large-scale pooled analysis of nine phase 2 or phase 3 registration trials. (ASCO 2025) - "Patients with advanced non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, and gastric cancer treated with camrelizumab monotherapy (Camre), camrelizumab plus apatinib (Camre-Apa), or camrelizumab plus chemotherapy (Camre-Chemo) were included. Although RCCEP occurred commonly, most events were mild without impact on camrelizumab treatment. RCCEP occurred early with 1-2 events mainly in each patient. The occurrence of RCCEP was positively associated with both short-term response and long-term survival, regardless of camrelizumab monotherapy or combination therapy."

P2 data • P3 data • Retrospective data • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Cancer • Hepatocellular Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

First-line camrelizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A nationwide, retrospective real-world study. (ASCO 2025) - "Compared with CameL, our patients had worse baseline characteristics and shorter duration of exposure to camrelizumab. Over one-fifth of patients selected single-agent chemotherapy as partner of camrelizumab. Even under this circumstance, this study still showed promising OS benefit with camrelizumab plus chemotherapy."

Metastases • Real-world • Real-world evidence • Retrospective data • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Camrelizumab plus chemotherapy or apatinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma: A double-cohort phase II study. (ASCO 2025) - P2 | "In Arm A, patients received camrelizumab (200 mg intravenous, day 1), followed by docetaxel (75 mg/m²) and cisplatin (75 mg/m²) or carboplatin (area under the curve 5) on day 2 every 3 weeks for up to six cycles, followed by camrelizumab monotherapy (200 mg intravenous, day 1, every 3 weeks). Camrelizumab combined with chemotherapy or apatinib demonstrated encouraging survival outcomes, with a favorable safety profile. These findings support further investigation of camrelizumab-based regimens as first-line treatments for patients with recurrent or metastatic HNSCC."

Clinical • Metastases • P2 data • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Assessing comparative efficacies of camrelizumab as a single or combination therapy in patients with hepatocellular carcinoma: A systematic review and network meta-analysis. (ASCO 2025) - "In this systematic review and network meta-analysis, we aim to compare CAM monotherapy with its combinations with other agents like Lenvatinib (LEN), Sorafenib (SOR), Rivoceranib (RIV), other tyrosine kinase inhibitors (TKI), hepatic arterial infusion chemotherapy (HAIC), and trans arterial chemoembolization (TACE). LEN-based combinations offered the highest survival benefits, suggesting a synergistic action in reducing tumor burden. While TACE based regimens offered the highest immediate response and control rate, these therapies were associated with a significantly higher risk of chemotherapy-associated adverse events. Combination therapies with LEN or RIV significantly reduced the risk of adverse events, implying a safer profile."

Combination therapy • Retrospective data • Review • Anemia • Hematological Disorders • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy of multimodal thermal therapy combined with immune checkpoint inhibitors and chemotherapy in unresectable pancreatic cancer with liver metastases. (ASCO 2025) - P=N/A | "Participants received MTT on at least one of the liver metastases combined with subsequent ICIs and chemotherapy (camrelizumab 200 mg IV on Day 1, gemcitabine 1000 mg/m² IV, and nab-paclitaxel 125 mg/m² IV on Days 1 and 8, every 3 weeks for 6 cycles), which was started on day 7 post MTT. MTT as a novel and safe promising therapy can systematically activate innate and adaptive antitumor immunity, potentially enhances the efficacy of immunotherapy and chemotherapy medicines. This modality offers new possibilities for downstaging and conversion therapy in PCLM. Clinical Trial Registration Number:NCT06307080."

Checkpoint inhibition • Clinical • IO biomarker • Autoimmune Hepatitis • Hepatology • Immunology • Liver Cancer • Oncology • Pancreatic Cancer • Solid Tumor